Twist Bioscience Continues Support for Next Generation of Synthetic Biologists Through Work with iGEM Competition
November 16 2020 - 6:59AM
Business Wire
-- Partners with Ginkgo Bioworks on “Ginkgo
Challenge” --
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced its continued
partnership with the International Genetically Engineered Machine
(iGEM) Foundation.
As a long-time supporter of iGEM, in 2019 Twist provided a
streamlined approach to change the way iGEM Competition teams
contribute to the Registry of Standard Biological Parts, a free
online database for synthetic biologists. Teams now submit their
part sequences and documentation to the Registry and Twist then
synthesizes samples of these parts for the following year’s
competition. In addition to synthesizing the parts, Twist is
providing all iGEM teams with 10kB of synthetic DNA to support
their project.
A new addition to the iGEM line up this year, Twist is
partnering with its customer Ginkgo Bioworks on the “Ginkgo
Challenge” during the iGEM workshop sessions. The Ginkgo Challenge
is a pitch competition to elevate ideas for how to make biology
easier to engineer. Teams will submit pitches through the weekend
here with the five top ideas selected on November 17th to pitch to
Ginkgo’s panel of three judges live on the 18th. The winner will
receive expert consultation in advanced biological design as well
as 50kB of synthetic DNA in Twist plasmids.
“The next generation of synthetic biologists across the globe
compete at iGEM, bringing their best ideas for solving global
challenges head-on,” said Emily Leproust, Ph.D., CEO and co-founder
of Twist Bioscience. “We, at Twist, are strong supporters of
employing science education, engineering prowess and creative
engagement to overcome obstacles. Through iGEM and the Ginkgo
Challenge, we have the opportunity to invest in and inspire the
bright minds that will drive our world forward, applying synthetic
biology and engineering principles and we cannot wait to see their
solutions.”
The International Genetically Engineered Machine (iGEM)
Foundation is an independent, non-profit organization dedicated to
the advancement of synthetic biology, education and competition,
and the development of an open community and collaboration. This is
done by fostering an open, cooperative community, and friendly
competition.
iGEM’s biggest program is the iGEM Competition. The iGEM
Competition gives students the opportunity to push the boundaries
of synthetic biology by tackling everyday issues facing the world.
Made up of primarily university students, multidisciplinary teams
work together to design, build, test, and measure a system of their
own design using interchangeable biological parts and standard
molecular biology techniques. Every year nearly 6,000 people
dedicate their summer to iGEM and then come together in the fall to
present their work and compete at the annual Jamboree.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; scientific
unknowns and new information relating to the SARS-CoV-2 virus; the
duration, extent and impact of the COVID-19 pandemic; supply chain
and other disruptions caused by the COVID-19 pandemic or otherwise;
uncertainties of the retention of a significant customer; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on August
12, 2020. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201116005451/en/
Investor Contact: Argot Partners Maeve Conneighton 212-600-1902
maeve@argotpartners.com
Media Contact: Angela Bitting 925- 202-6211
media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024